Revolution Rises 40% as Pancreatic Cancer Drug Doubles Survival

Why It Matters

The breakthrough offers the first substantial survival gain in advanced pancreatic cancer, a disease with a 13% five‑year survival rate, and could reshape treatment standards while boosting Revolution’s market valuation.

Key Takeaways

• Daraxonrasib doubled overall survival to 13.2 months vs 6.7 months
• Revolution shares rose ~40% to $134.80 after data release
• FDA priority voucher may shorten approval to 1‑2 months
• Phase 3 RASolute 302 interim data treated as final results
• Oral RAS inhibitor now entering first‑line and other cancer trials

Pulse Analysis

Pancreatic ductal adenocarcinoma remains one of oncology’s toughest challenges, with a U.S. five‑year survival rate of roughly 13 percent. Traditional options—surgery and chemotherapy—offer limited benefit once the disease has metastasized, and most tumors harbor KRAS mutations that drive aggressive growth. Daraxonrasib, an oral, non‑covalent multi‑selective RAS(ON) inhibitor, directly targets these mutations, representing a novel mechanistic approach that could finally address the “Achilles heel” many researchers have chased for years.

The Phase 3 RASolute 302 trial’s interim analysis revealed a striking overall‑survival improvement: patients lived an average of 13.2 months on daraxonrasib compared with 6.7 months on standard chemotherapy. Progression‑free survival also trended upward, prompting Revolution Medicines to label the data as final and move swiftly toward regulatory filing. Market reaction was immediate—stock surged nearly 40 percent to $134.80—while analysts highlighted the potential for synergistic use in first‑line settings. A Commissioner’s National Priority Voucher awarded in October 2025 could compress the FDA review timeline from the typical 10‑12 months to just one or two, accelerating patient access.

Beyond the immediate clinical impact, the results could reverberate across the biotech landscape. Revolution now has four Phase 3 programs featuring daraxonrasib, including RASolute 303 for treatment‑naïve pancreatic cancer and a late‑stage study in non‑small cell lung cancer. Success may trigger heightened M&A interest, as investors seek exposure to RAS‑targeted assets that promise both therapeutic differentiation and sizable market upside. For physicians, the data suggest a practice‑changing option that could become a new standard of care for previously treated metastatic pancreatic cancer, while patients gain a tangible hope for longer, quality‑adjusted survival.